Anticonvulsant. Antagonizes GluR5 kainate receptors (IC50 = 0.46 μM), acts as a positive allosteric modulator of GABAA receptor-mediated currents, inhibits Nav channels (IC50 = 48.9 μM) and inhibits L-type Ca2+ channels. Also inhibits carbonic anhydrase (CA) (Ki values are 0.1 and 0.2 μM at rat CA II and CA IV respectively), which lowers intracellular neuronal pH.
Deuterated analog also available.
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 339.36. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.95 mL||14.73 mL||29.47 mL|
|5 mM||0.59 mL||2.95 mL||5.89 mL|
|10 mM||0.29 mL||1.47 mL||2.95 mL|
|50 mM||0.06 mL||0.29 mL||0.59 mL|
References are publications that support the biological activity of the product.
Zona et al (1997) Topiramate attenuates voltage-gated sodium currents in rat cerebellar granule cells. Neurosci.Lett. 231 123 PMID: 9300637
Dodgson et al (2000) Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia 41 S35 PMID: 10768298
Gryder and Rogawski (2003) Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons. J.Neurosci. 23 7069 PMID: 12904467
Kaminiski et al (2004) Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist. Neuropharmacology 46 1097 PMID: 15111016
If you know of a relevant reference for Topiramate, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Topiramate, Topiramate supplier, GluR5, antagonists, anticonvulsant, GABAA, receptor, positive, allosteric, modulators, Glutamate, Kainate, Receptors, iGluR, Ionotropic, Topamax, Carbonic, anhydrases, 3620, Tocris Bioscience
Citations for Topiramate
Citations are publications that use Tocris products.
Currently there are no citations for Topiramate. Do you know of a great paper that uses Topiramate from Tocris? Please let us know.
Reviews for Topiramate
There are currently no reviews for this product. Be the first to review Topiramate and earn rewards!
Have you used Topiramate?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and EuropeSubmit a Review
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.